linjc16/ctgov huggingface dataset:
Online Survey on Computer Password Usage.

Study Overview
=================
Brief Summary
-----------------
Researchers at Towson University are conducting a study of computer password behaviors among users who have difficulty using their hands and arms (e.g., individuals with carpal tunnel syndrome, high level spinal cord injuries, etc.). Volunteers are needed to take a short 5-10 minute online survey. The survey is completely confidential and anonymous. If you would like to participate, please visit the URL below. Thank you. http://pages.towson.edu/jdarcy/securitysurvey.htm

Detailed Description
-----------------
Two researchers from the Department of Computer & Information Sciences at Towson University are seeking individuals who have difficulty using their hands and arms (e.g., as result of carpal tunnel syndrome, high level spinal cord injuries, etc.) to participate in a survey. The survey should take approximately 10 minutes to complete and all responses will remain completely confidential and anonymous. The purpose of the survey is to gain insight into the computing behaviors of individuals with upper-body motor impairments. We expect that the results will help researchers and system developers create more effective access control techniques to meet the special needs of this user population. The results should also assist employers in providing improved technical and procedural support to computer users that have difficulties using standard input devices. If you would like to take the online survey, please go to the following link: http://www.towson.edu/cosc/securitysurvey If you prefer a paper version of the survey, please send us an e-mail that contains your mailing address and we will send the survey to you. Contact information: John D'Arcy, Ph.D. (jdarcy@towson.edu) Jinjuan Feng, Ph.D. (jfeng@towson.edu) Department of Computer & Information Sciences Towson University 7800 York Road Towson, MD 21252 U.S.A.

Conditions
-----------------
Carpal Tunnel Syndrome

Intervention / Treatment
-----------------
* Behavioral: password usage


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Users who have difficulty using their hands or arms Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: password usage|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Warning Labels and College Students' Sugar-Sweetened Beverage Intake

Study Overview
=================
Brief Summary
-----------------
Sugar-sweetened beverages (SSBs) are one of the few dietary items causally linked to the development of obesity and chronic disease. SSB consumption among young adults are particularly concerning, because of the high levels of consumption and the influence of disease risk in later life. College students, particularly freshmen, are a captive audience when it comes to dietary consumption because many of them consume their meals in residential dining halls. We are currently working with Michigan Dining to implement warning labels on SSB fountain dispensers to examine whether carefully tailored signage could alter beverage choices of college students. The current study aims to assess changes in dietary intake before and after the labels are posted, in a representative sample of University of Michigan students who eat at residential dining halls.

Official Title
-----------------
The Impact of Warning Labels on Reducing College Students' Sugar-Sweetened Beverage Intake

Conditions
-----------------
Diet, Healthy

Intervention / Treatment
-----------------
* Behavioral: Sugar-sweetened beverage warning label


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Currently enrolled student at the University Visited one of three large dining halls at least 100 times in the first 1.5 months of the academic year Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention<br>Sugar-sweetened beverage warning label | Behavioral: Sugar-sweetened beverage warning label<br>* A sugar-sweetened beverage warning label appropriate for the college-aged population was developed and applied to beverage stations at one large campus dining hall<br>|
| No Intervention: Control<br>No label | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Beverage Intake Questionnaire-15 | The primary outcome is the mean servings of sugar-sweetened and non-sugar-sweetened beverages consumed in the past 30 days, as measured by a validated questionnaire | Four months |
Comparing Site-selection Strategies

Study Overview
=================
Brief Summary
-----------------
Several studies in the past have tried to deactivate electrodes that are less optimal to improve speech recognition outcomes. The study aims to compare the measures based on which the deactivation was performed. The investigators aim to first examine if the measures are strongly correlated each other, and then compare the deactivation effects across measures. These measures are mainly behavioral including electrode discrimination, amplitude modulation detection thresholds, low-rate and focused detection thresholds and electrode-modiolus distance. The endpoint of the study is speech recognition performance post deactivation.

Official Title
-----------------
Comparing Site-selection Strategies for Improving Speech Recognition Outcomes

Conditions
-----------------
Deafness

Intervention / Treatment
-----------------
* Behavioral: Site selection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Native speakers of English Cochlear Nucleus cochlear implant users or Advanced Bionics users Postlingually deafened Has had device experience for at least one year Can be child or adult at the time of enrollment Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cochlear implant users with Nucleus and AB devices<br>Speech recognition will be evaluated after poor electrodes are turned off. | Behavioral: Site selection<br>* Turning off electrodes on the electrode array based on imaging and psychophysical measures<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Speech recognition with deactivation | Electrodes will be evaluated based on (1) pitch discrimination (2) focused thresholds (3) amplitude modulation detection thresholds and (4) distances from the modious. Electrodes will be deactivated based on each of these measures and speech recognition will be evaluated to assess the effect of deactivation. The benefit of deactivation (speech recognition after deactivation minus before deactivation) will be derived for each measure. The measure that produces the greatest benefit will be identified. | 12 months post award notice and will take up to 3.5 years to complete |
Neurocognitive Impairment and Psychiatric Comorbidities in HIV-1

Study Overview
=================
Brief Summary
-----------------
To assess the prevalence and risk factors of neurocognitive impairment and psychiatric comorbidities in HIV infected patients who have undetectable viral load, have been on HAART for at least 1 year and have no history of CNS infection.

Detailed Description
-----------------
To understand how to prevent and treat HIV-associated neurocognitive impairment and psychiatric comorbidities in HIV-infected Thai individuals who don't have current AIDS related illness or current and prior central nervous system (CNS) infection, and have been well treated with HAART with undetectable HIV RNA.

Official Title
-----------------
Prevalence and Risk Factors of HIV-associated Neurocognitive Impairment and Psychiatric Comorbidities in HIV-1 Infected Thai Individuals With Undetectable Viral Load in the HAART Era.

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Procedure: lumbar puncture, MRI, MRS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed informed consent Evidence of HIV infection (confirmed positive ELISA and documented history of measurable HIV RNA) Age > 18 years old Plasma HIV RNA of < 50 copies/ml within 3 months prior to screening Have been on only NNRTI-based HAART regimen for the entire duration and for at least1 year. Exclusion Criteria: Current AIDS defining illnesses Current or history of previous CNS infection. Head injury with loss of consciousness greater than 1 hour Acute illness within 30 days prior to entry that, in the opinion of investigators, would prevent patients from completing the protocol required procedures. Known learning disability including dyslexia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>HIV infected adults with viral load < 50 copies/ml on NNRTI based HAART | Procedure: lumbar puncture, MRI, MRS<br>* lumbar puncture, MRI, MRS are only performed in patients with HIV associated dementia<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neuropsychological testing score |  | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
psychiatric, neuropsychiatric, neurocognitive, HIV related dementia, MCMD, HIV-1, Prevalence, risk factors of neurocognitive impairment and psychiatric comorbidities in HIV-1 infected patients with undetectable viral load in the HAART era., Treatment Experienced
Intrafractional Head Movement During Radiosurgery

Study Overview
=================
Brief Summary
-----------------
This study investigates the intrafractional accuracy of a frameless thermoplastic mask used for head immobilization during stereotactic radiotherapy. Non-invasive masks cannot completely prohibit head movements. Previous studies attempted to estimate the magnitude of intrafractional inaccuracy by means of pre- and postfractional measurements only. However, this might not be sufficient to accurately map also intrafractional head movements. Intrafractional deviation of mask-fixed head positions is measured in five patients during a total of 94 fractions by means of close-meshed repeated ExacTrac measurements conducted during the entire treatment session. From the obtained data the investigators evaluate the need to adjust safety margins around the gross tumor volume (GTV) whenever the investigated thermoplastic mask is used instead of invasive ring fixation.

Official Title
-----------------
Intrafractional 6D Head Movement With Mask Fixation During Stereotactic Intracranial RT-sessions

Conditions
-----------------
Brain Metastases, Adult

Intervention / Treatment
-----------------
* Device: ExacTrac position verification


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: single intracranial tumour or metastasis stereotactic radiation therapy planned immobilization with thermoplastic mask

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: ExacTrac position verification|Repeated measurement of patient head position with ExacTrac X-ray Monitoring|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 3D Head deviation | Length of 3D head position deviation during RT session | 5 to 20 days |
Cytidine-phosphate-guanosine (CpG) DNA in Hepatocellular Carcinoma Combination Therapy

Study Overview
=================
Brief Summary
-----------------
to observe the outcome of hepatocellular carcinoma patients under the combination treatment of transcatheter arterial chemoembolization (TACE) and CpG DNA

Official Title
-----------------
Cytidine-phosphate-guanosine (CpG) DNA in Hepatocellular Carcinoma Combination Therapy

Conditions
-----------------
Hepatocellular Carcinoma

Intervention / Treatment
-----------------
* Drug: CpG DNA
* Procedure: transcatheter arterial chemoembolization
* Drug: Placebo - Concentrate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: TNM (tumor node metastasis ) staging with non distant metastasis; no other tumors Exclusion Criteria: having received previous treatment for liver cancer

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CpG DNA<br>CpG DNA concentrate | Drug: CpG DNA<br>* CpG DNA concentrate<br>Procedure: transcatheter arterial chemoembolization<br>* transcatheter arterial chemoembolization (TACE) therapy for liver cancer<br>|
| Placebo Comparator: placebo<br>placebo concentrate | Procedure: transcatheter arterial chemoembolization<br>* transcatheter arterial chemoembolization (TACE) therapy for liver cancer<br>Drug: Placebo - Concentrate<br>* CpG DNA vehicle<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| survival time |  | 5 years | 
| metastasis free survival time |  | 5 years |
Drug-Drug Interaction Study to Assess the Effects of Multiple-Dose Administration of K-877 on the Pharmacodynamics and the Pharmacokinetics of Multiple-Dose Administration of Warfarin in Healthy Adult Volunteers

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the effects of K-877 on the pharmacodynamics and the pharmacokinetics of warfarin in healthy adults volunteers.

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Warfarin
* Drug: K-877


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject provides written informed consent before any study specific evaluation is performed. Subject is a healthy adult male or female volunteer between the ages of 18 and 45 years, inclusive. Subject has a body mass index of 18 to 30 kg/m², inclusive. Exclusion Criteria: Subject has clinically relevant abnormalities in the screening or check in assessments. Subject has clinically significant out-of-range PT, INR, activated partial thromboplastin time, fibrinogen, protein C, or protein S. Subject has abnormal prolongation of skin bleeding time at Screening.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Warfarin/Warfarin + K-877<br> | Drug: Warfarin<br> <br> Drug: K-877<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| International normalized ratio (INR) |  | 22 Days |
Effect of Furosemide on Confirmation of Ureteral Patency During Routine Cystoscopy

Study Overview
=================
Brief Summary
-----------------
This study evaluates if administration of IV furosemide leads to expedited confirmation of ureteral patency when compared to placebo (IV saline) in routine cystoscopy performed after urogynecologic surgery.

Detailed Description
-----------------
Cystoscopy is performed routinely after urogynecologic surgery to ensure there was no injury to the urinary tract (urethra, bladder, or ureters). In order to confirm that no damage occurred to the ureters, a jet of urine must be visualized from each ureteral opening. The time it takes to confirm this ureteral patency is variable and some sources suggest using furosemide to decrease the time it takes to see these jets. This study will evaluate what effect, if any, this medicine has on time to confirming ureteral patency.

Official Title
-----------------
Randomized Controlled Trial Evaluating Effect of Furosemide on Confirmation of Ureteral Patency During Routine Cystoscopy

Conditions
-----------------
Cystoscopy

Intervention / Treatment
-----------------
* Drug: furosemide
* Drug: Normal Saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Undergoing any urogynecologic surgery No allergy or contraindication to receiving furosemide Normal Creatinine/glomerular filtration rate Exclusion Criteria: Unable to consent, including if non English speaking Allergy or contraindication to receiving furosemide Intraoperative injury to the lower urinary tract

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: furosemide<br>furosemide 10mg (1mL) IV push for one dose | Drug: furosemide<br>* 10mg lasix given intraoperatively<br>* Other names: Lasix;|
| Placebo Comparator: placebo<br>normal saline 1mL IV push for one dose | Drug: Normal Saline<br>* Normal saline given intraoperatively as placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| time to ureteral patency | time to confirmation of ureteral patency in seconds | intra-operative | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| adverse effects from furosemide administration |  | immediately post operative (1-3 days post operatively) |
Regional Anesthesia for Thoracoscopic Surgery

Study Overview
=================
Brief Summary
-----------------
Aim of the study is to evaluate different regional anesthesia regimes for thoracoscopic surgery to evaluate their efficiency in (postoperative) pain control. Three regional anesthesia forms are evaluated: thoracic epidural anesthesia, (ultrasound-guided) serratus-anterior-plane-block an local infiltration with local anesthetic at the site of performing the thoracoscopy.

Detailed Description
-----------------
A prospective evaluation of different regional anesthesia regimes for thoracoscopic surgery to elucidate their efficiency in (postoperative) pain control. A day before surgery the patients gave their written informed consent to the study. Patients choose their favorite regional anesthesia out of the following: thoracic epidural anesthesia, (ultrasound-guided) serratus-anterior-plane-block an local infiltration with local anesthetic at the site of performing the thoracoscopy. In addition a general anesthesia was applied for the surgical procedure. Anesthesia was maintained using propofol and remifentanil. The patients pain score (visual analog scale), consumption of analgesic medication, satisfaction with pain therapy will be obtained one, six, 24 and 48 hours postoperatively. These prospective evaluation of different regional anesthetic techniques might provide us data to recommend a procedure for thoracoscopic surgery.

Official Title
-----------------
Regional Anesthesia for Thoracoscopic Surgery

Conditions
-----------------
Postoperative Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients scheduled for thoracoscopic surgery ASA 1-3 Exclusion Criteria: ASA 4 and 5 Age under 18 and over 80

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Epidural anesthesia<br>Patients receiving thoracic epidural anesthesia for thoracoscopic surgery. Standard regimen with 8-20 ml Ropivacaine 0,5% in the epidural catheter. Postopertive Ropivacaine 0,2% 6 ml/h via catheter were administered. | |
| Serratus-anterior-plane-Block<br>Patients receiving (ultrasound-guided) Serratus-anterior-plane-Block for thoracoscopic surgery. Standard regimen up to 20 ml Ropivacaine 0,5%, were installed. Postopertive Ropivacaine 0,2% 6 ml/h via catheter were administered. | |
| Local infiltration<br>Patients receiving local infiltration with up to 20 ml Ropivacaine 0,5% for thoracoscopic surgery (at the site of thoracoscopy) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative Pain (visual analog scale) | the postoperative Pain, evaluated with a visual analog scale (VAS), was obtained in the first 48 hours postoperatively after thoracoscopic surgery | 48 hours postoperative |